Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Hodgkin’s Disease (HD) A disease of lymph nodes with a predictable pattern of spread Epidemiology • Age: bimodal peak age –Third decade –After 50 • Gender: male to female = 1.3 to 1.0 Etiology and Risk Factors • Unknown • Possible etiologic factor –1) Familial factor –2) Viruses - EBV Signs and Symptoms • • • • HD is a lymph node-based malignancy Common = asymptomatic lymphadenopathy Systemic symptoms Extranodal involvement Location of Lymphadenopathy • 80% LN above the diaphragm –Anterior mediastinum –Cervical, supraclavicular, axillary Systemic Symptoms • 40% of patients -> systemic symptoms – B-symptom => Fever, Night sweat, Weight loss – Chronic pruritus Extranodal Involvement • “E” lesion by direct invasion • Hematogenous metastasis (Stage IV): spleen, lungs, liver, bone marrow Diagnosis • Biopsy • Pathology : “Reed - Sternberg Cell” – Diagnostic tumor cell – Must be identified – Large size, binucleated, large eosinophilic nucleoli Histology • 1. Lymphocyte predominant (LP) = few RS cells, good prognosis • 2. Nodular sclerosis (NS) = the most common, young adult, female • 3. Mixed cellularity (MC) = generalized lymphadenopathy • 4. Lymphocyte depletion (LD) = numerous RS cells, poor prognosis Staging : The Coltswolds Classification for HD • I: A single LN region or a lymphoid structure (eg., spleen, thymus, Waldeyer’s ring) • II: Two or more LN regions on the same side of the diaphragm • III: LN regions or structures on both sides of the diaphragm – 1: with/without involement of splenic, hilar, celiac, or portal nodes – 2: with involvement of paraaortic, iliac, or mesenteric nodes • IV: Extranodal site(s) beyond that designated E ( a single extranodal site, contiguous or proximal to a known nodal site) Designations applicable to any disease stage • A: No symptoms • B: Fever, drenching sweats, weight loss • X: Bulky disease – > 1/3 the width of the mediastinum – > 10 cm maximal dimension of nodal mass • E: Involvement of a single extranodal site, contiguous or proximal to a know nodal site Prognostic Factors • Stage of disease: the most important prognostic factor • Number of sites of involvement • Bulky disease ( particularly in the mediastinum) • B symptoms • Age • • • • Investigations 1. Imaging : CT scan of the chest/ abdomen 2. Lab tests: CBC, ESR, LDH 3. Bone marrow biopsy: B-symptoms 4. Staging laparotomy : consist of – – – – – Splenectomy LN sampling: celiac/splenic/hilar/paraaortic/paracaval/iliac nodes Wedge/needle biopsy of the liver open iliac crest Bone Marrow Biopsy Oophoropexy Treatment • Stage I-II = Radiotherapy • Stage III-IV = Chemotherapy Radiotherapy • Subtotal lymphoid irradiation = Mantle + Paraaortic field • Mantle field = base of mandible to diaphragm – Cover LN above diaphragm -> submandibular, cervical, supraclavicular, infraclavicular, axillary, mediastinum, hilar • Dose = 3,600 cGy Side Effects of Radiotherapy • Acute – N/V, Dermatitis, Fatigue • Delay – – – – – Pneumonitis Herpes zoster infection Subclinical hypothyroidism Infertility Secondary malignancies • secondary solid tumors ( lung, breast) • chemotherapy -> most common = leukemia Non-Hodgkin’s Lymphoma Heterogeneous group of lymphoproliferative malignancies Epidemiology • The incidence has been increasing worldwide. • This increase is more marked for older persons. Etiology and Causative Factors • The origin is UNCERTAIN. • Causative factors with a predisposition – Immunosuppression – Infectious agents (EBV, HTLV-1, Herpes type 8, H.pylori) NHL • Usually originates in lymphoid tissues • Can spread to other organs • Prognosis depends on the histologic type, stage and extent of disease, age, and treatment Clinical Manifestations • Asymptomatic LN enlargement (most common presentation) • 1) Location of lymphadenopathy – most common = neck, inguinal, and abdominal LNs • 2) Systemic symptoms – fever, weight loss, night sweats ( usually heralding more advanced disease) • 3) Primary extranodal lymphoma – depend on the site of origin Staging Evaluation • Pathologic diagnosed by an experienced hematopathologist. • Staging Evaluation includes: – History + Physical Exam – Lab : CBC, LDH – Bone marrow biopsy – Chest X-Ray – CT abdomen and pelvis/chest – Gallium scan Histology: 2 prognostic groups • Indolent lymphoma • Aggressive lymphoma Staging: Ann Arbor System (commonly used) • I: A single nodal region (I) or single extralymphatic site (IE) • II: 2 or more nodal regions on the same side of diaphragm(II) or a single localized extralymphatic site and its regional nodes on the same side of diaphragm (IIE) • III: Nodal regions on both sides of the diaphragm • IV: Diffuse or disseminated involvement of 1 or more extralymphatic organs with/without associated nodal involvement Designations applicable to any stage • A: No symptoms • B: Weight loss, unexplained fever, night sweats • E: Localized involvement of extralymphatic tissue • S: Spleen involvement Treatment • Indolent Lymphoma – Stage I + II = RT – Stage III + IV = Chemotherapy + RT • Aggressive Lymphoma – Stage I + II = combined modality ( Chemotherapy + RT) – Stage III + IV = Chemotherapy ( Doxorubicin based) Radiotherapy • Involve-field RT: – Involved region + first-echelon adjacent LN region • Extended field RT: – involve field + second-echelon adjacent LN region Example Radiation Dose: • Indolent: 2,500 - 3,500 cGy • Aggressive: 3,500 - 4,500 cGy Late effects of treatment • Normal tissue toxicity • Secondary cancers